Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
7,341 total articles
Silver Lake Partners sold 299,933 shares of Dell Technologies Inc Class C Common Stock on March 20, 2026, generating about $49.3 million at prices between $163.51 and $165.49 per share. The same entities converted significant blocks of Class B Common Stock into Class C shares at a $0 conversion price. Dell's stock has risen to $176.91, near a 52-we…
Hinge Health Chief Financial Officer James Budge sold 10,906 Class A shares on March 23, 2026, for roughly $465,138 across three transactions executed under a Rule 10b5-1 trading plan. The company’s stock trades around $40.91, down about 12% year-to-date, while analysts hold mixed ratings and price targets amid strong recent revenue growth and an o…
Silver Lake Group and affiliated investment vehicles disposed of $49.3 million worth of Dell Technologies Class C shares on March 20, 2026, selling at prices between $163.51 and $165.49 per share. The transactions included multiple Silver Lake funds and followed concurrent conversions of Class B common stock into Class C shares. Separately, Dell di…
James Pursley, president of Hinge Health, executed a pre-arranged sale of 15,000 Class A shares on March 23, 2026, generating roughly $633,927. The transactions were carried out under a Rule 10b5-1 plan and occurred in three tranches. Following the sales Pursley holds 732,104 Class A shares. Analysts continue to project an optimistic earnings outlo…
A Bristow Group Inc. director sold 1,000 shares of the company's common stock on March 23, 2026, at $45.00 per share, resulting in proceeds of $45,000. After the sale the director holds 17,455 shares. The transaction occurred as VTOL traded near $45.48 following a 42% one-year gain. Separately, Bristow reported fourth-quarter 2025 EPS of $0.61 vers…
Serina Therapeutics Chief Scientific Officer Randall Moreadith sold 6,500 shares on March 23, 2026, realizing $18,567, while exercising options to acquire the same number of shares at a nominal strike. The firm is progressing a Phase 1b study for SER-252 after FDA IND clearance, but faces a NYSE notice over listing criteria and continues to burn ca…
Sun Kang, a director at Amprius Technologies (NASDAQ: AMPX), sold 217,869 shares on March 23, 2026, in two transactions totaling about $4.1 million. The trades were completed under a Rule 10b5-1 plan adopted in August 2025. The company reported fourth-quarter 2025 results that beat expectations, recorded record quarterly revenue, added over 100 cus…
Turtle Beach Corp director Katherine Lee Scherping reported insider sales in two filings, with transactions occurring on March 20 and March 23, 2026, and the company also announced the resignation of director Terry Jimenez effective Friday. The filings indicate Scherping sold shares at prices between $11.50 and $11.62 for a reported total value of …
Maurice Sciammas, Executive Vice President for Worldwide Sales and Marketing at Monolithic Power Systems Inc (NASDAQ: MPWR), disposed of 30 shares on March 20, 2026, in a transaction valued at $32,852. The sale, carried out under a Rule 10b5-1 plan established last November, left Sciammas with 178,644 shares of direct ownership, worth roughly $196 …
Quantum-Si Inc. Chief Financial Officer Jeffry R. Keyes sold a total of 8,655 Class A shares across two transactions on March 20 and March 23, 2026, raising roughly $7,246. The filings show the disposals were sell-to-cover trades to satisfy withholding taxes tied to vested restricted stock units. The trades occurred while QSI shares hovered around …
On March 23, 2026, OnKure Therapeutics President and CEO Nicholas A. Saccomano sold 86 shares of Class A common stock to satisfy tax-withholding from vested restricted stock units. The transaction totaled $357 at a weighted average price of $4.1565. Separately, H.C. Wainwright lowered its price target on the company to $27 from $34, citing an expec…
John S. Vieceli, Chief Product Officer at Quantum-Si Inc., completed two sell-to-cover transactions on March 20 and March 23, 2026, disposing of 21,997 shares of Class A common stock for approximately $18,416. The sales were executed at weighted average prices of $0.8483 and $0.8266, respectively. The company recently reported mixed fourth-quarter …
On March 23, 2026, OnKure Therapeutics CFO Jason A. Leverone sold 301 shares of Class A common stock at a weighted average price of $4.1565 to satisfy tax withholding tied to vested restricted stock units. The transaction, disclosed on a Form 4 filing, generated $1,251 in proceeds and followed a share price range of $3.995 to $4.235. Separately, H.…
Christian LaPointe, General Counsel and Corporate Secretary of Quantum-Si Inc (NASDAQ: QSI), disposed of 11,959 shares across two transactions on March 20 and March 23, 2026, generating roughly $10,012. The sales were made under a required sell-to-cover arrangement to satisfy withholding tax on vested restricted stock units. The trades come as QSI …
Jeffrey Alan Hawkins, President and CEO of Quantum-Si Inc (NASDAQ: QSI), completed two sell-to-cover transactions on March 20 and March 23, 2026, disposing of 23,777 Class A shares for a combined $19,906, according to a Form 4 filing. The sales were conducted to cover tax obligations from the vesting of restricted stock units. The filings also show…
Ashoo Gupta, vice president of finance and controller at 4D Molecular Therapeutics, sold 390 shares of common stock for $3,357 on March 20, 2026, while also converting restricted stock units into additional shares. The transactions occur as the company draws analyst focus for its retinal disease clinical programs and as its share price has risen sh…
Teresa L. Dick, chief administrative officer and executive vice president of Diamondback Energy Inc. (NASDAQ: FANG), sold 5,000 shares on March 20, 2026, for $193.00 per share, a transaction valued at $965,000. The sale occurred while the stock was trading close to its 52-week peak and following a quarter in which the company delivered stronger-tha…
Diamondback Energy Executive Vice President and COO Daniel N. Wesson sold 5,000 shares on March 20, 2026, for roughly $959,776. The transaction was filed on a Form 4 with the SEC. The sale comes amid strong fourth-quarter 2025 production results, analyst price target increases, and a substantial secondary share offering that will not benefit the co…
Pharmacy Investors, LLC disclosed the sale of 827,636 Class A shares of Guardian Pharmacy Services, Inc. (NASDAQ: GRDN) on March 20, 2026, in a Form 4 filing with the SEC. The shares were sold at $29.6825 each for a total of $24,566,305. The sale followed an underwriting agreement dated March 18, 2026. Since the sale, GRDN has risen to $37.57, trad…
Exzeo Group Chief Executive Officer Paresh Patel acquired 2,000 shares of company common stock at $14.99 per share on March 24, 2026, for a total of $29,980. The purchase comes while the shares have fallen 39% year-to-date and are trading at $14.81; Exzeo reported fourth-quarter and full-year 2025 results that matched analysts' forecasts, with dilu…
Guardian Pharmacy Services CFO David K. Morris sold 187,855 Class A shares on March 20, 2026, for roughly $5.576 million under an underwriting agreement dated March 18, 2026. The shares have since risen to $37.57, near their 52-week high, while analysts lifted price targets after the company's solid fourth-quarter results. A recent underwritten off…
Hims & Hers Health CFO Oluyemi Okupe sold 9,217 shares of Class A stock on March 20, 2026, generating about $219,066, and exercised options to acquire 4,489 shares. The transactions, carried out under a Rule 10b5-1 plan, follow the company’s partnership with Novo Nordisk and recent corporate developments that have driven a sharp share-price rally.
Marcus Corporation President Michael Reade Evans sold a small block of company shares on March 20, 2026, while the company reported a fourth-quarter fiscal 2025 earnings-per-share beat alongside a slight revenue shortfall. Evans retains a substantial direct stake and holds a portfolio of stock options that vest over time. Analysts remain constructi…
Viatris Inc. Chief Accounting Officer and Corporate Controller Paul Campbell sold 21,350 shares on March 23, 2026, generating proceeds of $283,538 at a weighted average price of $13.2805. The transaction comes amid the company's forward financial guidance to 2030, recent regulatory approval in Japan, and a series of analyst price-target revisions. …
Daxor Corp's Chief Medical Officer, John Jefferies, reported two acquisitions totaling 5,941 shares of common stock on March 20, 2026. The filings list the transactions at a $0 price per share. The moves come as the stock trades at $10.34, while the company has reported strong operating revenue growth, increased net assets and completed a registere…
